The Host Julie Rovner KFF Health News @jrovner @julierovner.bsky.social Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A…
The new Trump administration could be coming for your snacks. For years, the federal government has steered clear of regulating junk food, fast food, and ultra-processed food. Now attitudes are changing. Some members of President-elect Donald Trump’s inner circle are gearing up to battle “Big Food,” or the companies that make most of the food…
From a marketing perspective, there are three significant trends to watch in 2025 — strategic brand partnerships, AI-driven healthcare information delivery, and the fundamental shift in social media engagement paradigms. The post Healthcare Marketing: Key Trends Shaping 2025 appeared first on MedCity News.
We are entering an age of at home testing and the team at Reperio just raised $14m to make weight, blood pressure and cholesterol/blood sugar testing available at home. But this is a relatively complex series of tests, intended to get people who haven’t been to a primary care doctor back into the system. How…
Avandra Imaging, a federated network for de-identified imaging data, emerged from stealth at HLTH — as well as announced a partnership with Datavant. The post Avandra Imaging Emerges from Stealth to Solve a Last-Mile Problem in Medical Research appeared first on MedCity News.
In recent months, federal agents have camped out in the lobby of a Southern California hospital, guarded detained patients — sometimes shackled — in hospital rooms, and chased an immigrant landscaper into a surgical center. U.S. Immigration and Customs Enforcement agents have also shown up at community clinics. Health providers say that officers have tried…
When the FDA announced in January, before President Joe Biden’s term ended, that it would ban a dye called red dye No. 3 in food and ingested drugs, the federal agency cited just one 1987 study on rats to support its action. The industry-funded study, based on data from two prior studies, was led by…
Arrowhead Pharmaceuticals’ RNAi drug plozasiran, brand name Redemplo, is now the second FDA-approved therapy for familial chylomicronemia syndrome, an inherited lipid disorder. Beyond its claims of safety and dosing advantages, Arrowhead set a dramatically lower price for its first commercial product, which will compete against an Ionis Pharmaceuticals drug. The post With FDA Approval for…
This fact sheet provides an overview of health coverage for immigrants based on data from the 2023 KFF/LA Times Survey of Immigrants, the largest nationally representative survey focused on immigrants and discusses potential implications of incoming Trump administration policies for coverage of immigrants.
Dr. Bhattacharya, a US COVID policy critic, has been nominated by Trump to lead the country’s top public funder of medical research